aTyr Pharma, Inc.
ATYRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeaTyr Pharma, Inc. aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and. Valued at $47.6M, ATYR is a micro-cap name in its sector. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Market Cap
$47.6M
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
-0.77
EPS (TTM)
$-0.74
EPS (Fwd)
$-0.63
ROE
-105.6%
ROA
-51.8%
Cash
$66.5M
Total Debt
$11.7M
Free CF
-$32.7M
52W Change
-90.7%
Annual Financials
Cash vs Debt
Where ATYR stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ATYR finished 33.78% below its 150-day moving average ($0.74) and 35.53% below its 200-day moving average ($0.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATYR overbought or oversold?
At the July 15, 2026 close, ATYR's RSI(14) was 44.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $66.5M in cash comfortably exceeding the $11.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$32.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -105.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $10.4M (2022) to $190K (2025), a 98% decline worth watching.
With a beta below 0.7, aTyr Pharma, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ATYR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for aTyr Pharma, Inc. and its sector.